A phase 2 trial of Brigimadlin in advanced solid tumours, run by Boehringer Ingelheim, active and no longer recruiting.
A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine is a phase 2 interventional study registered as NCT06619509 by Boehringer Ingelheim, with 90 participants enrolled, started 2024-12-30 and due to reach its primary completion in 2030-12-30. Interventions recorded: Brigimadlin.
Shares Boehringer Ingelheim, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.